- <sup>i</sup>Impact of axial spondylarthritis on quality of life: results from the European Map of Axial
   Spondyloarthritis (EMAS) study in France
- 3 4 TITLE PAGE
- 4 5 6
- Short running head: axial spondyloarthritis and QoL

Full title: Impact of axial spondylarthritis on quality of life: results from the European Map
of Axial Spondyloarthritis (EMAS) study in France

- 10
- 11 Authors: Joanna Kedra, Laurent Grange, Pascal Claudepierre, René-Marc Flipo, Marco
- 12 Garrido-Cumbrera, Françoise Alliot-Launois, Emilie Desfleurs, Laure Gossec
- 13

Name	Statu s	Affiliation	Email adress	ORCI D numb er	Disclosures of interest
Joanna Kedra	MD, MS c	Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France. & Pitié-Salpêtrière hospital, AP- HP.Sorbonne Université, Rheumatology department, Paris, France.	jkedra.pro@gmail.com	0000- 0003- 3535- 3183	None
Pascal Claudepier re	MD, Ph D	Rheumatology department, Henri Mondor hospital, AP- HP, Université Paris Est Créteil, EA 7379 – EpiDermE, Créteil, France	pascal.claudepierre@aphp .fr		Has received honoraria for participatin g in EMAS scientific committee from Novartis Pharma
René-Marc Flipo	MD, Ph D	Rheumatology department, Roger Salengro University hospital, Lille	renemarc.flipo@chru-lille.fr		Has received honoraria for participatin g in EMAS

Moree	MD	University, Lille, France Health &	maumbroro@uo.co	0000	scientific committee from Novartis Pharma
Marco Garrido- Cumbrera	MD, Ph D	Territory Research (HTR), Universidad de Sevilla, Spain	<u>mcumbrera@us.es</u>	0000 - 0001 - 9727 - 1189	Has received honoraria for participatin g in EMAS scientific committee from Novartis Pharma
Françoise Alliot- Launois		Association Française de Lutte Antirhumatism ale (AFLAR), Paris, France	francoisealliotlaunois@gmail.com		None
Emilie Desfleurs	Ph D	Medical Affairs, Novartis Pharma, Rueil- Malmaison, France	emilie.desfleurs@novartis. com		Novartis employee
Laurent Grange	MD, Ph D	Rheumatology department, Grenoble Alpes University Hospital, Hôpital Sud, Échirolles, France & Association Française de Lutte Antirhumatism ale (AFLAR), Paris, France	LGrange@chu-grenoble.fr		None
Laure Gossec	MD, Ph D	Sorbonne Université, INSERM, Institut Pierre Louis	laure.gossec@aphp.fr	0000- 0002- 4528- 310X	research grants: Amge n, Galapagos, Janssen, Lilly,

d'Epidémiologie et de Santé Publique, Paris, France. & Pitié-Salpêtrière hospital, AP- HP.Sorbonne Université, Rheumatology department, Paris, France.	Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sansfi
	Bioepis, Sanofi- Aventis, UCB.

14

15 Source(s) of support in the form of grants or industrial support: This study was funded by

- 16 Novartis Pharma.
- 17 Corresponding author:
- 18 Joanna Kedra, MD, MSc, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie
- 19 et de Santé Publique, and Pitié-Salpêtrière hospital, AP-HP.Sorbonne Université, Rheumatology
- 20 department, 47-83, boulevard de l'Hôpital 75013 Paris France
- 21 Email: jkedra.pro@gmail.com Tel : +33 1 42 17 84 21 Fax : +33 1 42 17 79 59

22

Ethics and consent: All patients agreed to their participation through informed opt-in consent. In this study, no clinical trial was conducted. As it was not an interventional study, no ethics committee approval was required in France. EMAS global results have already published.

- Key indexing terms: Spondylitis, Ankylosing; Quality of life; Patient Reported Outcome
- 29 Measures; Surveys and Questionnaires
- 30 Manuscript details:
- 31 Word count: 817/800
- 32 Tables/figures: 2/2
- 33 References: 11/10

The impact of axSpA on patients' quality of life has been well assessed in terms of body structures and functions, but much less in terms of social interactions and activities, work, and fears related to social interactions or activities (1).

A better understanding of patients' daily difficulties is a key issue in rheumatology, as it could positively affect patients' well-being and the management of their disease (2). In this context, a large patients' survey, the European Map of Axial Spondyloarthritis (EMAS) study, was performed to explore patients' perceptions of axSpA (3–6). The aim of the present study was to assess the impact of axSpA on quality of life, and particularly on social interactions, social activities, working issues and fears, using data from the EMAS French participants.

EMAS was conducted in 13 European countries in 2017-2018 (4); the findings for
French patients are presented here. Participants had to be aged≥18 years, to self-report
a diagnosis of axSpA (either radiographic or non-radiographic), and to report having seen
a healthcare professional for axSpA in the 12 months prior to participation.

The impact of axSpA was evaluated by an online questionnaire developed by an international scientific committee. Four categories of impact were assessed: social interactions (5 items: with spouse, family, friends and colleagues, and sexual intercourse frequency), frequency of leisure activities and social life (4 items: restaurants, cultural outings, travels, sports), working issues (current sick leave), and fears for the future. Sociodemographic and disease-related data, as well as self-reported comorbidities (anxiety, depression, overweight/obesity, fibromyalgia), were also collected.

Impact of axSpA on quality of life was assessed qualitatively: worse or much worse 56 social interactions for at least one of the five items, less or much less frequent social 57 activities for at least one of the four items, current sick leave, and at least a positive 58 response to a fear-related question. The key outcome here was major impact, defined as 59 having an impact on 2 or more aspects of quality of life (among social interactions, social 60 activities, sick leave or fears). Statistics were descriptive, without imputation of missing 61 data. Univariable and multivariable logistic regression models were built in order to 62 determine the factors associated with major impact. All variables with p-value < 0.20 in 63 64 univariable analysis were included in the multivariable model (7).

Data from 638 patients were analyzed: mean age  $41.5\pm11.1$  years, 77% women, mean disease duration  $6.9\pm8.2$  years. Disease was active (mean BASDAI:  $5.9\pm1.7$ ), and 19.1% participants were on biologics at the time of the survey. Participants frequently reported anxiety (N=312, 50.4%), being overweight/obese (N=237, 38.2%) or depression (N=199, 32.8%).

Overall, 615 (96.4%) patients reported any of the four impacts among social interactions, social life, sick leave and fears (Figure 1). A major impact on quality of life (i.e.,  $\geq$  2 categories impacted) was reported by 575 participants (90.1%).

A total of 505 participants (79.4%) reported a negative impact of axSpA on social interactions with partners, family, friends or coworkers, particularly in terms of frequency of sexual intercourse. 548 (86.2%) participants engaged in fewer leisure activities due to their axSpA and more specifically going to restaurants or physical activity in nearly 80% of cases. More than half of participants were employed at the time of the survey, while 75 (12%) and 87 (14%) participants were respectively on temporary or permanent sick leave.

Finally, 585 (91.7%) participants reported fears for the future, the main fear reported by
the surveyed participants being alteration of daily activities (N=453, 71.0%).

Factors associated with major impact on quality of life in univariable and confirmed in multivariable analysis were: being unemployed (odd ratio [OR]=3.3, 95% confidence interval [CI] 1.7, 10.0), biologic use (OR=3.0, 95%CI 1.6, 5.3), female gender (odds ratio, OR=2.6, 95%CI 1.4, 4.8), low educational level (OR=2.0, 95%CI 1.1, 3.3), and reporting at least one comorbidity (OR=1.6, 95%CI 1.2, 2.2) (Table 1).

This study brings to light that more than 90% of patients with axSpA in France 86 describe a major impact of axSpA (defined here as having at least two categories of 87 quality of life among social activities, social interactions, sick leave, and fears impacted 88 89 by the disease) on their social and working life, in a context of fears for the future. Factors associated with an increased risk of major impact were not related to the activity of the 90 disease, except receiving biologics; however, this association was probably secondary to 91 92 an indication bias, as these treatments are prescribed in the most severe/active axSpA, which are more likely to affect patients' quality of life (8). Factors which were significantly 93 associated with major impact were rather related to patients' background, experience and 94 identity, which is concordant with previous studies (9–11). Indeed, sociodemographic 95 characteristics influence patients' understanding and perception of their disease, and 96 ultimately influence their experience and quality of life. 97

98 These findings underline the need of a multidisciplinary approach to enable a more 99 global and efficient management of axSpA, and ultimately improve patient's quality of life. 100

- 101

## Acknowledgements:

The authors acknowledge the EMAS working group. The EMAS project is a collaboration led by the Health & Territory Research group of the University of Seville, the Ankylosing Spondylitis International Federation, and a steering committee composed of patient representatives and internationally recognized rheumatologists, psychologists, and researchers specialized in axSpA.

Novartis funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication.

## **References:**

- 1. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet Lond Engl. 2017;390:73-84.
- Santiago MG, Marques A, Kool M, Geenen R, da Silva JAP. Invalidation in Patients with Rheumatic Diseases: Clinical and Psychological Framework. J Rheumatol. 2017;44:512-8.
- 3. Garrido-Cumbrera M, Poddubnyy D, Gossec L, et al. The European Map of Axial Spondyloarthritis: Capturing the Patient Perspective—an Analysis of 2846 Patients Across 13 Countries. Curr Rheumatol Rep. 2019;21:19.
- 4. Garrido-Cumbrera M, Navarro-Compán V, Zarco P, et al. Atlas of axial spondyloarthritis in Spain 2017: Study design and population. Reumatol Clin. 2019;15:127-32.
- 5. Garrido-Cumbrera M, Poddubnyy D, Gossec L, et al. Gender differences in patient journey to diagnosis and disease outcomes: results from the European Map of Axial Spondyloarthritis (EMAS). Clin Rheumatol. 2021;40:2753-61.
- 6. Garrido-Cumbrera M, Bundy C, Navarro-Compán V, et al. Patient-reported Impact of Axial Spondyloarthritis on Working Life: Results from the EMAS survey. Arthritis Care Res [Internet]. 2021;73:1826-1833.
- 7. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.
- 8. Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatology. 2020;59:iv79-89.
- 9. Kreis S, Molto A, Bailly F, et al. Relationship between optimism and quality of life in patients with two chronic rheumatic diseases: axial spondyloarthritis and chronic low back pain: a cross sectional study of 288 patients. Health Qual Life Outcomes. 2015;13:78.
- Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky. Curr Rheumatol Rep. 2018;20:35.
- 11. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198-206.

Figure 1. Venn diagram for the four domains of quality of life in axSpA patients




Table 1. Factors associated with major impact on quality of life (i.e. having at least two domains impacted by axSpA)

Variable	Mean (SD)	Mean (SD)	p-value for	p-value for	OR (95% CI) for
	or N(%) in	or N(%) in	univariable	multivariable	multivariable
	population	population	analysis	analysis	analysis
	with ≥ 2	with < 2			
	impacts	impacts			
Age	41.5 (±10.9)	42.2 (±12.9)	0.62	N/A	N/A
Gender	461 (80.2)	36 (57.1)	<0.001	0.002	2.6 (1.4, 4.8)
(Female)					
Educational	295 (51.3)	19 (30.2)	0.002	0.029	2.0 (1.1, 3.3)
level (high					
school or less)					
Married/living in	370 (64.3)	42 (66.7)	0.72	N/A	N/A
couple (Yes)					
Employment	268 (48.7)	13 (21.0)	<0.001	0.001	3.3 (1.7, 10.0)
status					
(Unemployed)					
Smoking (Yes)	188 (32.7)	19 (30.2)	0.68	N/A	N/A
Symptoms	14.3 (±10.5)	13.5 (±9.3)	0.57	N/A	N/A
duration					
bDMARD (Yes)	366 (64.6)	22 (36.7)	<0.001	<0.001	3.0 (1.6, 5.3)
Comorbidities (0	1.4 (±1.2)	0.7 (±1.1)	<0.001	0.001	1.6 (1.2, 2.2)
to 4, odds ratio					
for one					
additional					
comorbidity)					

Footnote: axSpA: axial spondyloarthritis; bDMARD: biologic disease modifying anti-rheumatic drugs,

95%CI: 95% confidence interval; OR: odd ratio

Comorbidities corresponded to overweight/obesity, depression, fibromyalgia, and anxiety

<sup>1</sup> This is a pre-copyediting, author-produced PDF of an article accepted for publication in The Journal of Rheumatology following peer review. The definitive publisherauthenticated version [Kedra, J., Claudepierre, P., Flipo, R. M., Garrido-Cumbrera, M., Alliot-Launois, F., Desfleurs, E., ... & Gossec, L. (2022). Impact of Axial Spondyloarthritis on Quality of Life: Results From the European Map of Axial Spondyloarthritis (EMAS) Study in France. The Journal of Rheumatology, 49(10), 1176-1178.] is available online at: <u>https://doi.org/10.3899/jrheum.210864</u>